Traded Aug 5 – Aug 21, 2025 · largest single transaction ~$51
Show all 5 transactions
Aug 18, 2025~$40 · 13 sh @ $3.11
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CPIX · NASDAQ · Pharmaceutical Preparations
Cumberland Pharmaceuticals (CPIX) · oqro.io/stocks/CPIX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$5.80+0.59 (+11.32%)
Close of Nov 17, 2026, vs Nov 16 · end-of-day, not a live quote
No open-market purchase by an insider of Cumberland Pharmaceuticals was filed in the last 90 days. The latest on record was on Sep 12, 2025.
Since 2010, Cumberland Pharmaceuticals insiders reported 2,795 open-market purchases and 102 sales on Forms 4 and 5, with purchases in 11 different years, most recently 2025.
No open-market sale by an insider of Cumberland Pharmaceuticals (CPIX) was filed with the SEC in the last 90 days.
No trade in Cumberland Pharmaceuticals (CPIX) was disclosed by a member of Congress in the last 12 months.
Cumberland Pharmaceuticals's next results are expected on Mar 1, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+205.3% (+$3.90) from Nov 17, 2025 to Nov 17, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.90 on Nov 17, 2025 to $5.80 on Nov 17, 2026 (+205.3%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Nashville,, Tn.
Last 12 months
+205.3%
Market value
$87M
S&P 500 +10.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 300K shares sold short (2.0% of shares outstanding), −10.6% vs the previous count, 1.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$2.16M
+1155.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$987K
This quarter −$1.51M, a year earlier $163K
Net debt
—
Debt —, cash $80.6M, at Sep 30, 2026
Net income, last 12 months
$68.8M
Operating profit covers interest -16.5x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 10, 2026.
Revenue, fiscal 2025
$44.5M
+17.6% vs the year before
Net income, fiscal 2025
−$2.84M
A loss for the year
Shares outstanding
15M
As of Nov 11, 2026
In fiscal 2025 the company spent $263K buying back its own shares. Cash actually paid, from its cash-flow statement.
Traded Aug 5 – Aug 21, 2025 · largest single transaction ~$51
Aug 18, 2025~$40 · 13 sh @ $3.11
Aug 5, 2025~$51 · 13 sh @ $3.92
DetailsOfficial recordAug 8, 2025~$44 · 13 sh @ $3.39
DetailsOfficial recordAug 21, 2025~$42 · 13 sh @ $3.25
DetailsOfficial recordAug 13, 2025~$38 · 13 sh @ $2.94
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
0 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in scleroderma, diffuse, idiopathic pulmonary fibrosis. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Insiders of Cumberland Pharmaceuticals reported 2,795 open-market purchases and 102 sales since 2010; purchases in 11 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $42K504×504 trades | — |
| 2024 | $38K232×232 trades | — |
| 2022 | $100K683×683 trades | — |
| 2021 | $200K836×836 trades | — |
| 2020 | $36K87×87 trades | — |
| 2019 | $278K434×434 trades | $695K77×77 trades |
| 2018 | $8.4K5×5 trades | — |
| 2017 | $136K6×6 trades | $224K3×3 trades |
| 2016 | $5K1×1 trade | $143K4×4 trades |
| 2015 | — | $105K3×3 trades |
| 2014 | — | $218K3×3 trades |
| 2013 | — | $60K1×1 trade |
| 2012 | — | $428K2×2 trades |
| 2011 | $258K3×3 trades | $651K7×7 trades |
| 2010 | $198K4×4 trades | $1.93M2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last results
Nov 10, 2026
Within the 30 days after it, until Dec 10, 2026
Next results, expected
Mar 1, 2027
Purchases after results
41%
716 of 1736 insider purchases since 2009 came within 30 days after a results announcement
From Cumberland Pharmaceuticals's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Cumberland Pharmaceuticals's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
On the public record for Cumberland Pharmaceuticals over the 12 months to Nov 18, 2026: 2 clinical trials.